0001493152-18-002426.txt : 20180221 0001493152-18-002426.hdr.sgml : 20180221 20180221061549 ACCESSION NUMBER: 0001493152-18-002426 CONFORMED SUBMISSION TYPE: 15-12G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20180221 DATE AS OF CHANGE: 20180221 EFFECTIVENESS DATE: 20180221 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ProPhase Labs, Inc. CENTRAL INDEX KEY: 0000868278 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232577138 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12G SEC ACT: 1934 Act SEC FILE NUMBER: 000-21617 FILM NUMBER: 18626993 BUSINESS ADDRESS: STREET 1: 621 N. SHADY RETREAT ROAD CITY: DOYLESTOWN STATE: PA ZIP: 18901 BUSINESS PHONE: 2153450919 MAIL ADDRESS: STREET 1: 621 N. SHADY RETREAT ROAD CITY: DOYLESTOWN STATE: PA ZIP: 18901 FORMER COMPANY: FORMER CONFORMED NAME: QUIGLEY CORP DATE OF NAME CHANGE: 19930328 15-12G 1 form15-12g.htm

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 15

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

Under Section 12(g) of the Securities Exchange Act of 1934

 

Commission File Number 0-21617

 

ProPhase Labs, Inc.

(Exact name of registrant as specified in its charter)

 

621 N. Shady Retreat Road

Doylestown, Pennsylvania 18901

(215) 345-0919

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

Title of each class of securities covered
by this Form		   Titles of all other classes of securities for which a
duty to file reports under section 13(a) or 15(d)
remains
Common Stock Purchase Rights 1   Common Stock, $0.0005 par value per share

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1) [X]
Rule 12g-4(a)(2) [  ]
Rule 12h-3(b)(1)(i) [  ]
Rule 12h-3(b)(1)(ii) [  ]
Rule 15d-6 [  ]

 

Approximate number of holders of record as of the certification or notice date: None

 

1 The Common Stock Purchase Rights (the “Rights”) expired on February 20, 2017 pursuant to the terms of the Rights Agreement, dated June 18, 2018, as amended on January 6, 2017 and February 20, 2018, by and between ProPhase Labs, Inc. (the “Company”) and American Stock Transfer & Trust Company, LLC, as rights agent. The Company initially filed a Form 8-A to register the Rights on September 18, 1998.

 

 

 

 
 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, ProPhase Labs, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Date: February 21, 2018   By: /s/ Ted Karkus
      Name: Ted Karkus
      Title: Chairman of the Board and Chief Executive Officer